Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
- 14 July 2013
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 38 (5) , 447-459
Abstract
Tumour necrosis factor (TNF)-antagonists have an established role in the treatment of inflammatory bowel diseases (IBDs), however, subtherapeutic drug levels and the formation of anti-drug antibodies (ADAs) may decrease their efficacy. The evidence supporting the use of therapeutic drug monitoring (TDM) based clinical algorithms for infliximab (IFX) and their role in clinical practice will be discussed. The literature was reviewed to identify relevant articles on the measurement of IFX levels and antibodies-to-infliximab. Treatment algorithms for IBD have evolved from episodic monotherapy used in patients refractory to all other treatments, to long-term combination therapy initiated early in the disease course. Improved remission rates have been observed with this paradigm shift, nevertheless many patients ultimately lose response to therapy. Although empiric dose optimization or switching agents constitute the current standard of care for secondary failure, these interventions have not been applied in an evidence-based manner and are probably not cost-effective. Multiple TDM-based algorithms have been developed to identify patients that may benefit from measurement of IFX and ADA levels to guide adjustments to therapy. Therapeutic drug monitoring offers a rational approach to the management of secondary failure to IFX. This concept has gained momentum based on evidence from case series, cohort studies and post-hoc analyses of randomised controlled trials.Keywords
This publication has 47 references indexed in Scilit:
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to InfliximabClinical Gastroenterology and Hepatology, 2013
- Review article: infliximab for Crohn’s disease treatment - shifting therapeutic strategies after 10 years of clinical experienceAlimentary Pharmacology & Therapeutics, 2011
- The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximabAlimentary Pharmacology & Therapeutics, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A ReviewAmerican Journal of Gastroenterology, 2009
- Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2008
- Adalimumab Induction Therapy for Crohn Disease Previously Treated with InfliximabAnnals of Internal Medicine, 2007
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's diseaseGut, 2001
- Tumour-necrosis-factor antibody treatment in Crohn's diseaseThe Lancet, 1993